Dr. Reddy’s Laboratories (RDY) Comments on Recent Media Reports
Up)
Dr. Reddy’s Laboratories (NYSE: RDY) wishes to clarify that the media reports highlighting its troubles with the US health authorities related to certain promotional material for Fondaparinux Sodium are misleading .
Dr. Reddy’s had received a communication from the Division of Professional Promotion (DPP), US FDA directing for changes related to certain promotional material for Fondaparinux Sodium for Injection. The company has already addressed all matters raised by the DPP, US FDA in the letter issued on January 10, 2012. The DPP informed Dr. Reddy's Laboratories on January 24, 2012 that the matters are now considered closed.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Dr. Reddy’s had received a communication from the Division of Professional Promotion (DPP), US FDA directing for changes related to certain promotional material for Fondaparinux Sodium for Injection. The company has already addressed all matters raised by the DPP, US FDA in the letter issued on January 10, 2012. The DPP informed Dr. Reddy's Laboratories on January 24, 2012 that the matters are now considered closed.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- LinkedIn (LNKD) Shares Lower as ITG Warns of Q2 Pricing, Volume Weakness
- Star Scientific (CIGX) Shows Strength on Move Above Key Level
- Dr. Reddy’s Labs (RDY) Launches Generic OTC Prevacid (NVS)
Create E-mail Alert Related Categories
Corporate News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
